Optimalizace strategií retence, trvání a vysazení pro farmakoterapii poruch užívání opioidů (RDD)
NIDA-CTN-0100: Optimalizace retence, trvání a strategií vysazení pro farmakoterapii poruch užívání opioidů (RDD)
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The main objectives of this study are:
- To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
- To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
- To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.
The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
-
-
California
-
Tarzana, California, Spojené státy, 91356
- Tarzana Treatment Centers, Inc.
-
-
Connecticut
-
Bridgeport, Connecticut, Spojené státy, 06610
- Liberation Programs, Inc.
-
-
Florida
-
Clearwater, Florida, Spojené státy, 33760
- Operation PAR
-
Jacksonville, Florida, Spojené státy, 32204
- Gateway Community Services
-
Orlando, Florida, Spojené státy, 32806
- Aspire Health Partners
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21229
- Mountain Manor / Maryland Treatment Centers
-
-
Massachusetts
-
Belmont, Massachusetts, Spojené státy, 02478
- McLean Hospital
-
Fall River, Massachusetts, Spojené státy, 02720
- Stanley Street Treatment and Resources, Inc.
-
Newton, Massachusetts, Spojené státy, 02458
- Square Medical Group, LLC
-
-
Missouri
-
Cape Girardeau, Missouri, Spojené státy, 63703
- Gibson Center for Behavioral Change
-
-
New Hampshire
-
Lebanon, New Hampshire, Spojené státy, 03766
- Dartmouth Hitchcock - ATP
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- University of New Mexico Addiction and Substance Abuse Program
-
-
New York
-
New York, New York, Spojené státy, 10016
- Bellevue Hospital Center
-
-
Oregon
-
Roseburg, Oregon, Spojené státy, 97470
- Adapt Integrated Health Care
-
Winston, Oregon, Spojené státy, 97496
- Adapt Integrated Health Care
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- Center for Psychiatric and Chemical Dependency Services (CPCDS)
-
Pittsburgh, Pennsylvania, Spojené státy, 15219
- Internal Medicine Recovery Engagement Program (IM-REP)
-
-
South Carolina
-
Conway, South Carolina, Spojené státy, 29526
- Shoreline Behavioral Health Services
-
-
Utah
-
Salt Lake City, Utah, Spojené státy, 84108
- Huntsman Mental Health Institute / University of Utah
-
-
West Virginia
-
Morgantown, West Virginia, Spojené státy, 26505
- Chestnut Ridge Center
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria for Retention Phase:
- 18 years of age or older;
- Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
- Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
- If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
- Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
- In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
- Willing and able to provide written informed consent;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Retention Phase:
-
Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
- Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
Known allergy or sensitivity to preferred medication or its components;
-
Maintenance on methadone at the time of signing consent;
-
For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;
-
For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).
Inclusion Criteria for Discontinuation Phase:
- 18 years of age or older;
- Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
- Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
- Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
- If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
- Willing to be randomized to either MM or to MMD;
- Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
- Able to speak English sufficiently to understand the study procedures;
- If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).
Exclusion Criteria for Discontinuation Phase:
-
Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:
- Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
- Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
-
Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);
-
For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;
-
If female, currently pregnant or breastfeeding or planning on conception;
-
Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;
-
Meets current DSM-5 criteria for any current alcohol use disorder;
-
Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;
-
Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);
-
Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Faktorové přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Retention: SL-BUP standard dose + MM
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentální: Retention: SL-BUP high dose + MM
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentální: Retention: XR-BUP + MM
Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
|
|
Experimentální: Retention: XR-NTX + MM
Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Ostatní jména:
|
|
Experimentální: Retention: SL-BUP standard dose + MMR
Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Retention: SL-BUP high dose + MMR
High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Retention: XR-BUP + MMR
Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Retention: XR-NTX + MMR
Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Ostatní jména:
MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Discontinuation: Discontinue SL-BUP with SL-BUP + MM
Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MM consists of standard Medical Management and the usual counseling at the treatment program. |
|
Experimentální: Discontinuation: Discontinue SL-BUP with XR-BUP + MM
Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
|
|
Experimentální: Discontinuation: Discontinue XR-BUP with XR-BUP + MM
Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
|
|
Experimentální: Discontinuation: Discontinue XR-NTX with XR-NTX + MM
Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program. |
MM consists of standard Medical Management and the usual counseling at the treatment program. Monthly dosing of extended-release injectable naltrexone
Ostatní jména:
|
|
Experimentální: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD
Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Daily dosing of sublingual buprenorphine-naloxone
Ostatní jména:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD
Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD
Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Weekly/monthly dosing of extended-release injectable buprenorphine
Ostatní jména:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
|
Experimentální: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD
Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component. |
Monthly dosing of extended-release injectable naltrexone
Ostatní jména:
MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Retention: Continuous retention in MOUD treatment through 26 weeks
Časové okno: Retention: from randomization through week 26
|
Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period. |
Retention: from randomization through week 26
|
|
Discontinuation: Completed Discontinuation without Relapse
Časové okno: Discontinuation: from randomization through week 24 follow up
|
Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued. |
Discontinuation: from randomization through week 24 follow up
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Retention KS1: Weekly opioid abstinence
Časové okno: Retention: from randomization through week 26
|
Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26. |
Retention: from randomization through week 26
|
|
Retention KS2: Treatment effectiveness
Časové okno: Retention: at week 26
|
Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26. |
Retention: at week 26
|
|
Retention KS3: Treatment by baseline severity
Časové okno: Retention: at week 26
|
Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no). |
Retention: at week 26
|
|
Discontinuation KS1: Completed Discontinuation
Časové okno: Discontinuation: from randomization through week 24 follow up
|
Completed Discontinuation without regard to relapse status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS2: Relapse
Časové okno: Discontinuation: from randomization through week 24 follow up
|
Relapse - separate binary outcome without regard to discontinuation status |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS3: Safety
Časové okno: Discontinuation: from randomization through week 24 follow up
|
Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal. |
Discontinuation: from randomization through week 24 follow up
|
|
Discontinuation KS4: Treatment effectiveness
Časové okno: Discontinuation: at end of taper (EoT) and week 24 follow up
|
Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint). |
Discontinuation: at end of taper (EoT) and week 24 follow up
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
- Vrchní vyšetřovatel: Roger Weiss, MD, Harvard Medical School/McLean Hospital
- Vrchní vyšetřovatel: John Rotrosen, MD, NYU Langone Health
Publikace a užitečné odkazy
Obecné publikace
- Shulman M, Meyers-Ohki S, Novo P, Provost S, Ohrtman K, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemp Clin Trials. 2025 Mar;150:107816. doi: 10.1016/j.cct.2025.107816. Epub 2025 Jan 20.
- Shulman M, Provost S, Ohrtman K, Novo P, Meyers-Ohki S, Van Veldhuisen P, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Nunes EV, Weiss RD. Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trial. Contemp Clin Trials. 2024 Jul;142:107543. doi: 10.1016/j.cct.2024.107543. Epub 2024 Apr 23.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Poruchy související s narkotiky
- Duševní poruchy
- Poruchy související s látkami
- Chemicky indukované poruchy
- Poruchy související s opioidy
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, fúzované kroužek
- Farmaceutické přípravky
- Alkaloidy
- Polycyklické aromatické uhlovodíky
- Polycyklické sloučeniny
- Heterocyklické sloučeniny, 4 nebo více prstenů
- Kombinace drog
- Naloxon
- Morfináni
- Alkaloidy opiátů
- Heterocyklické sloučeniny, přemostěný prsten
- Fenanthrenes
- Buprenorfin, naloxon, kombinace léčiv
- Buprenorfin
- Vivitrol
Další identifikační čísla studie
Další identifikační čísla studie
- 19-01363
- UG1DA015831 (Grant/smlouva NIH USA)
- CTN-0100 (Jiný identifikátor: NIDA Clinical Trials Network)
- UG1DA013035 (Grant/smlouva NIH USA)
- 20-PRS-057 (Jiný identifikátor: Biomedical Research Alliance of New York (BRANY) sIRB)
- 146193 (Jiný identifikátor: FDA/IND#)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).
Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.
The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).
Časový rámec sdílení IPD
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .